Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: Janssen Vaccine Effective Against Two Virus Variants In South Africa Study, But Gets EU Thrombocytopenia Warning

Executive Summary

Data show that more than 480 million COVID-19 vaccines have now been administered in the EU/European Economic Area, with Malta, Iceland and Ireland leading the way in the percentage of people now fully vaccinated.

You may also be interested in...



Coronavirus Notebook: Richer Countries Urged To Pay ‘Fair Share’ Of Vaccine & Drug Financing, EU Assesses Comirnaty Boosters

EFPIA has welcomed an evidence-based report on the regulatory flexibilities used in Europe during the pandemic and how they could be further employed in future. The EMA’s drug safety committee is looking at more reports of menstrual disorders with mRNA vaccines.

EU Heart Condition Warning For COVID-19 Vaccines Comirnaty And Spikevax

All four coronavirus vaccines authorized for marketing in the EU/European Economic Area have had their safety information updated because of various adverse events including myocarditis, pericarditis and capillary leak syndrome.

UK First To Approve Moderna’s Bivalent COVID-19 Vaccine

The mRNA-1273.214 vaccine will add to the UK’s armory for protecting people against coronavirus over the coming winter season.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel